In the present study, we further investigated the differences in the peripheral blood inflammatory indicator IL-6 and other cytokines in patients with GLM and those with benign breast tumors, which provided an innovative idea for exploring the pathogenesis, clinical diagnosis, and treatment of GLM. The gene discussed is IL6; the disease is breast benign neoplasm.